Degenerative Neurological and Neuromuscular Disease

Degenerative Neurological and Neuromuscular Disease is a peer-reviewed open access journal published online only by Dove Medical Press since 2011, devoted to the biological and clinical basis of degenerative neurological and neuromuscular disease, ranked first quartile of Clinical Neurology in the Emerging Sources Citation Index with a 2025 Journal Impact Factor of 9.9《退行性神经与神经肌肉疾病》（Degenerative Neurological and Neuromuscular Disease）是多芙医学出版公司（Dove Medical Press）自 2011 年起纯在线出版的同行评审开放获取期刊，专注退行性神经与神经肌肉疾病的生物学和临床基础，在新兴来源期刊引文索引（ESCI）的临床神经病学类居第一分区，2025 年影响因子为 9.9。

Scope

• The publisher describes it as an international, peer-reviewed, open access journal focusing on research into the biological and clinical basis of degenerative neurological diseases including multiple sclerosis, Huntington's disease, Alzheimer's disease, Parkinson's disease and Friedreich's ataxia出版方称其为聚焦退行性神经疾病之生物学与临床基础研究的国际同行评审开放获取期刊，病种包括多发性硬化、亨廷顿病、阿尔茨海默病、帕金森病与弗里德赖希共济失调。
• Its listed topics begin with the natural history, epidemiology, detection and screening of these disorders, and continue with pathophysiology, causative agents and vectors, cellular research and biomarkers其列明主题始于上述疾病的自然史、流行病学、检出与筛查，续以病理生理、致病因子与媒介、细胞研究与生物标志物。
• It further covers the identification of biotargets and of agents with novel mechanisms of action, the optimal clinical use of existing agents including combination therapies, complementary and alternative medicine, and palliative care其范围还包括生物靶点与作用机制新颖之药剂的识别、含联合治疗在内的既有药物的最佳临床应用、补充与替代医学以及姑息治疗。
• The topic list closes with patient adherence, quality of life and satisfaction and with health economic evaluations, so service-level and cost questions sit beside molecular research主题列表以患者依从性、生活质量与满意度以及卫生经济学评估收尾，使服务层面与成本议题和分子研究并列。
• Articles published in the two most recent volumes include original research, reviews and case reports, ranging from a ten-year web-based cohort study of disability and health-related quality of life in multiple sclerosis in the Netherlands to a mechanistic perspective on utrophin pathways in Duchenne muscular dystrophy最近两卷刊载的文章含原创研究、综述与病例报告，题材从荷兰多发性硬化残疾与生活质量之十年网络队列研究，到杜氏肌营养不良中肌营养不良蛋白旁路机制的评述。
• The journal is indexed in PubMed and PubMed Central, is listed in the Emerging Sources Citation Index and in the Open Access Initiative, and the publisher reports 28553 annual downloads and views for it该刊被（PubMed）与（PubMed Central）收录，列于新兴来源期刊引文索引与开放获取计划，出版方报告其年下载与浏览量为 28553 次。
• It has no print sister record and is identified only by the online serial number 1179-9900, with open access terms set out by the publisher for each accepted article该刊无印刷版记录，仅以在线国际标准刊号 1179-9900 标识，开放获取条款由出版方就每篇录用文章予以明确。

History

• The journal was started by Dove Medical Press in 2011, and volume one carried six articles, the earliest of them an editorial printed on page 1 in March of that year该刊由多芙医学出版公司创立于 2011 年，第 1 卷刊载 6 篇文章，最早一篇为当年 3 月列于第 1 页的社论。^[1]
• From the outset it mixed therapeutic and clinical questions, publishing in its first year an evaluation of glycopyrrolate for chronic drooling and a survey of the clinical utility of cannabinoids for spasticity in multiple sclerosis该刊自创刊即兼及治疗与临床议题，首年即发表格隆溴铵治疗慢性流涎的评价与大麻素用于多发性硬化痉挛之临床效用的综述。
• Licensing of those early deposits is recorded in the DOI registry under the Creative Commons Attribution-NonCommercial licence at version 3.0, the framework the publisher used before moving to its current open access terms早期存档文章的许可在（DOI）登记库中记为知识共享署名非商业性使用 3.0 版许可，即出版方在改用现行开放获取条款前所采用的框架。
• One volume appears each year, so 2026 is volume 16 and the publisher's page counts 154 published articles over the whole run, with ten in volume 16 and nine in volume 15该刊每年出版一卷，2026 年为第 16 卷，出版方页面统计全程共发 154 篇，其中第 16 卷 10 篇、第 15 卷 9 篇。
• Dove Medical Press is stated to be part of the Taylor and Francis Group, the academic publishing division of Informa PLC, whose registered office is in London, and the earliest deposits of this title were submitted under the name Informa UK Limited多芙医学出版公司被标注为（Taylor and Francis Group）之一员、英富曼（Informa PLC）的学术出版分部，其登记办公地在伦敦，而该刊最早的存档提交记录所用名称为（Informa UK Limited）。
• Its recorded impact factor was 3.2 for 2024 and 9.9 for 2025, and the journal metrics page gives a five-year impact factor of 7.0 for 2025 together with the first quartile position其影响因子 2024 年为 3.2，2025 年为 9.9，期刊指标页另给出 2025 年五年影响因子 7.0 与第一分区位次。

Editors

• The journal's editors page names Professor Thomas Muller as editor-in-chief, heading the Department of Neurology and working as consultant in neurology and psychiatry at St. Joseph Hospital Berlin-Weissensee in Germany该刊编辑页列有主编（Thomas Muller）教授，任德国柏林韦森塞圣约瑟夫医院（St. Joseph Hospital Berlin-Weissensee）神经科主任并任神经与精神科顾问医师。
• His published biography gives his research as the use of functional and morphologic brain imaging techniques, namely MRI, fMRI, SPECT and PET, in the diagnosis and progression of neurodegenerative disorders such as Parkinson's disease, together with neuropharmacological trials of putative neuroprotective compounds其官方简介称其研究为以功能与形态学脑成像技术，即（MRI）、（fMRI）、（SPECT）与（PET），诊断并评估帕金森病等神经退行性疾病的进展，另包括潜在神经保护药物的神经药理试验。
• The journal metrics page reports an acceptance rate of 10 percent, a figure the publisher publishes beside its citation metrics期刊指标页报告其录用率为 10%，该数值由出版方与引用指标并列公布。
• The journal states that it is a member of and subscribes to the principles of the Committee on Publication Ethics, and it offers an accelerated publication route for accepted work该刊声明其为国际出版伦理委员会成员并遵守其原则，同时为录用文章提供加速出版通道。
• The publisher checks all submitted manuscripts for plagiarism through the Crossref similarity service powered by iThenticate, and it invites researchers to register as peer reviewers of the journal出版方经由（iThenticate）驱动的（Crossref）相似性检测服务对全部投稿进行抄袭核查，并邀请研究者登记为该刊评审人。
• Authors pay an article publishing charge set by location, recorded as 3278 US dollars for the United States, Canada and rest of world, 2428 pounds sterling for the United Kingdom and 2918 euros for the eurozone作者按所在区域支付文章处理费，记录为美国加拿大及其他地区 3278 美元、英国 2428 英镑、欧元区 2918 欧元。
• Board membership is recruited openly through the parent group's editorial recruitment portal, so the roster of editors beside the editor-in-chief and the terms of their service are to be taken from the publisher's own listing编委经母集团的编辑招募门户公开征聘，故主编之外的编委名单与服务任期一律以官方口径为准。